TAK Stoklara Genel Bakış

Takeda Pharmaceutical Company Limited, Japonya'da ve uluslararası alanda farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi, pazarlanması ve dışarıya lisanslanması faaliyetlerini yürütmektedir. Daha fazla detay

TAK temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 62.5% daha düşük bir oranda işlem görüyor

Kazançların yılda 21.61% oranında artması öngörülüyor

Risk Analizi

4.8% temettüsü kazançlar tarafından iyi karşılanmıyor

Kar marjları (2.4%) geçen yılın (3.4%) altında

Yüksek borç seviyesine sahip

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Takeda Pharmaceutical Company Limited Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Takeda Pharmaceutical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	JP¥14.57
52 Haftanın En Yüksek Seviyesi	JP¥15.43
52 Haftanın En Düşük Seviyesi	JP¥12.58
Beta	0.26
1 Aylık Değişim	-4.02%
3 Aylık Değişim	3.63%
1 Yıllık Değişim	11.05%
3 Yıllık Değişim	-1.35%
5 Yıllık Değişim	-25.28%
Halka arzdan bu yana değişim	-31.44%

Son Haberler & Güncellemeler

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Mar 13

Recent updates

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Mar 13

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Jan 31

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Dec 07

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Oct 07

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Jun 06

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

Mar 03

Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play

Oct 24

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

Aug 31

Takeda: Upside Case Strengthening, Looking To 15x Earnings

Jun 21

Hissedar Getirileri

	TAK	US Pharmaceuticals	US Pazar
7D	3.3%	-1.7%	-2.7%
1Y	11.1%	-11.6%	9.0%

Getiri vs. Endüstri: TAK geçen yıl % -11.6 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: TAK geçen yıl boyunca % 9 oranında getiri sağlayan US Piyasası ile eşleşti.

Fiyat Oynaklığı

Is TAK's price volatile compared to industry and market?
TAK volatility
TAK Average Weekly Movement	3.4%
Pharmaceuticals Industry Average Movement	11.3%
Market Average Movement	8.0%
10% most volatile stocks in US Market	17.1%
10% least volatile stocks in US Market	4.1%

İstikrarlı Hisse Senedi Fiyatı: TAK son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: TAK 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1781	49,281	Christophe Weber	www.takeda.com

Takeda Pharmaceutical Company Limited, Japonya'da ve uluslararası alanda farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi, pazarlanması ve lisanslanması faaliyetlerini yürütmektedir. Gastroenteroloji, nadir hastalıklar, plazma kaynaklı tedaviler, immünoloji, onkoloji ve nörobilim alanlarında farmasötik ürünler sunmaktadır. Şirket ürünlerini Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA markaları altında sunmaktadır, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA ve Alunbrig markaları.

Takeda Pharmaceutical Company Limited Temel Bilgiler Özeti

Takeda Pharmaceutical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TAK temel i̇stati̇sti̇kler
Piyasa değeri	US$45.65b
Kazançlar(TTM)	US$757.37m
Gelir(TTM)	US$32.15b

60.3x

F/K Oranı

1.4x

P/S Oranı

TAK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TAK gelir tablosu (TTM)
Gelir	JP¥4.58t
Gelir Maliyeti	JP¥1.58t
Brüt Kâr	JP¥3.00t
Diğer Giderler	JP¥2.89t
Kazançlar	JP¥107.93b

Son Raporlanan Kazançlar

Mar 31, 2025

Sonraki Kazanç Tarihi

Jul 30, 2025

Hisse başına kazanç (EPS)	69.10
Brüt Marj	65.51%
Net Kâr Marjı	2.36%
Borç/Özkaynak Oranı	65.1%

TAK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

4.8%

Mevcut Temettü Verimi

287%

Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/23 05:53
Gün Sonu Hisse Fiyatı	2025/05/23 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Takeda Pharmaceutical Company Limited 37 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Hazim Bahari	CFRA Equity Research

TAK Stoklara Genel Bakış

Ödüller

Risk Analizi

Takeda Pharmaceutical Company Limited Rakipler

Zoetis

Bristol-Myers Squibb

Royalty Pharma

Merck

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Recent updates

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Takeda Pharmaceutical Company Limited (TSE:4502) announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda: Upside Case Strengthening, Looking To 15x Earnings

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency